Journal of Clinical Pediatrics ›› 2020, Vol. 38 ›› Issue (3): 209-.doi: 10.3969/j.issn.1000-3606.2020.03.012

Previous Articles     Next Articles

Propafenone combined with propranolol in the treatment of catecholaminergic polymorphic ventricular tachycardia: a case report and literature review

 ZHANG Li, LI Yun, WANG Jianyi, XIAO Tingting, XIE Lijian, XU Meng   

  1. Department of Cardiology, Children’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200062, China
  • Published:2020-04-07

Abstract:  Objective To investigate the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT). Method The clinical data of CPVT in a child was analyzed and the related literature was reviewed. Results A boy, aged 5 years and 2 months, had intermittent precardiac discomfort for more than 8 months and two syncope attacks triggered by exercises. The 24-hour ECG and treadmill test showed that ventricular arrhythmia occurred when sinus heart rate was > 110 bpm. When the heart rate was increased, the frequency of ventricular arrhythmia was increased, and the bidirectional and polymorphic ventricular tachycardia could be seen. Gene detection showed RYR2 gene mutation c.6886G> A (p.E2296K). After the treatment with high dose of propranolol, the symptoms were not relieved and the ECG examination did not improve significantly, but the symptoms were improved with the addition of polymorphic. After one-year follow-up, the child had no chest discomfort after exercise and no ventricular arrhythmia was found in the 24-hour ECG and treadmill test. Conclusions The main clinical features of CPVT are bidirectional and/or pleomorphic ventricular tachycardia induced by exercise or emotional excitation. Syncope and sudden death are the main clinical manifestations. Propafenone may be a promising alternative or combinated for the treatment of CPVT.

Key words:  catecholaminergic polymorphic ventricular tachycardia; cardioverter defibrillator; β-blocker;  propafenone